Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA24868
Max Phase: Preclinical
Molecular Formula: C8H10ClN5O2
Molecular Weight: 243.65
Molecule Type: Small molecule
Associated Items:
ID: ALA24868
Max Phase: Preclinical
Molecular Formula: C8H10ClN5O2
Molecular Weight: 243.65
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1nc(Cl)c2ncn(COCCO)c2n1
Standard InChI: InChI=1S/C8H10ClN5O2/c9-6-5-7(13-8(10)12-6)14(3-11-5)4-16-2-1-15/h3,15H,1-2,4H2,(H2,10,12,13)
Standard InChI Key: BSFGGUCAZGXDGK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 243.65 | Molecular Weight (Monoisotopic): 243.0523 | AlogP: 0.03 | #Rotatable Bonds: 4 |
Polar Surface Area: 99.08 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 2.28 | CX LogP: -0.03 | CX LogD: -0.03 |
Aromatic Rings: 2 | Heavy Atoms: 16 | QED Weighted: 0.58 | Np Likeness Score: -0.66 |
1. Kim D, Kim H, Chae Y. (1994) Design and synthesis of 6-fluoropurine acyclonucleosides : potential prodrugs of acyclovir and ganciclovir, 4 (11): [10.1016/S0960-894X(01)80350-4] |
2. Robins MJ, Hatfield PW, Balzarini J, De Clercq E.. (1984) Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine "acyclic" nucleoside analogues., 27 (11): [PMID:6092636] [10.1021/jm00377a018] |
3. Helguera AM, Rodríguez-Borges JE, García-Mera X, Fernández F, Cordeiro MN.. (2007) Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set., 50 (7): [PMID:17341060] [10.1021/jm061445m] |
4. Johnson BM, Shu YZ, Zhuo X, Meanwell NA.. (2020) Metabolic and Pharmaceutical Aspects of Fluorinated Compounds., 63 (12): [PMID:32182061] [10.1021/acs.jmedchem.9b01877] |
Source(1):